Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Regulatory protein RhlR is a central transcriptional regulator within the complex quorum-sensing (QS) hierarchy of the opportunistic pathogen Pseudomonas aeruginosa (UniProt P54292). It functions as a LuxR-type receptor that is activated upon binding its cognate autoinducer, N-butyryl-L-homoserine lactone (C4-HSL), which is produced by the synthase RhlI (Mukherjee et al., 2017). Once activated, RhlR forms a dimer and binds to specific DNA sequences (lux boxes) to trigger the expression of genes involved in the production of secondary metabolites and virulence factors, such as rhamnolipids, pyocyanin, and elastase (O'Loughlin et al., 2013). These factors are essential for the bacteria's ability to form robust biofilms, evade the host immune system, and cause tissue damage during chronic infections, particularly in patients with cystic fibrosis or compromised immune systems (Eickhoff et al., 2021). Because RhlR controls virulence rather than essential growth processes, it is considered a high-priority target for anti-virulence therapy. Inhibiting RhlR aims to disarm the pathogen and enhance its clearance by the host immune system or conventional antibiotics, potentially reducing the selective pressure that leads to traditional antibiotic resistance (Mukherjee et al., 2017; Eickhoff et al., 2021).
Competitive antagonism of the autoinducer binding site or disruption of the RhlR-DNA binding interface to inhibit the transcription of virulence-associated genes.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Regulatory protein RhlR (RhlR) (RhlR).